PCI-27483 was originally developed as a highly potent and selective inhibitor of the serine protease Factor VIIa (FVIIa) when in complex with tissue factor (TF) that has a normal physiological role in the initiation of the blood clotting cascade in response to an injured blood vessel wall.29 However, TF has been shown to be overexpressed in numerous primary tumors and is associated with tumor progression and worsened survival in cancer patients. This evidence concerns the gene F3 and neoplasm.